Outcome of COVID-19 infections in patients with adrenal insufficiency and excess
Background: Information on clinical outcomes of coronavirus disease 19 (COVID-19) infection in patients with adrenal disorders is scarce. Methods: A collaboration between the European Society of Endocrinology (ESE) Rare Disease Committee and European Reference Network on Rare Endocrine Conditions...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2023-03-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/12/4/EC-22-0416.xml |
| _version_ | 1797881656669896704 |
|---|---|
| author | Hanna F Nowotny Jillian Bryce Salma R Ali Roberta Giordano Federico Baronio Irina Chifu Lea Tschaidse Martine Cools Erica LT van den Akker Henrik Falhammar Natasha M Appelman-Dijkstra Luca Persani Guglielmo Beccuti Ian L Ross Simona Grozinsky-Glasberg Alberto M Pereira Eystein S Husebye Stefanie Hahner S Faisal Ahmed Nicole Reisch |
| author_facet | Hanna F Nowotny Jillian Bryce Salma R Ali Roberta Giordano Federico Baronio Irina Chifu Lea Tschaidse Martine Cools Erica LT van den Akker Henrik Falhammar Natasha M Appelman-Dijkstra Luca Persani Guglielmo Beccuti Ian L Ross Simona Grozinsky-Glasberg Alberto M Pereira Eystein S Husebye Stefanie Hahner S Faisal Ahmed Nicole Reisch |
| author_sort | Hanna F Nowotny |
| collection | DOAJ |
| description | Background: Information on clinical outcomes of coronavirus disease 19 (COVID-19) infection in patients with adrenal disorders is scarce.
Methods: A collaboration between the European Society of Endocrinology (ESE) Rare Disease Committee and European Reference Network on Rare Endocrine Conditions via the European Registries for Rare Endocrine Conditions allowed the collection of data on 64 cases (57 adrenal insufficiency (AI), 7 Cushing’s syndrome) th at had been reported by 12 centres in 8 European countries between January 2020 and Dec ember 2021.
Results: Of all 64 patients, 23 were males and 41 females (13 of those children) with a median age of 37 and 51 years. In 45/57 (95%) AI cases, COVID -19 infection was confirmed by testing. Primary insufficiency was present in 45/57 p atients; 19 were affected by Addison’s disease, 19 by congenital adrenal hyperpla sia and 7 by primary AI (PAI) due to other causes. The most relevant comorbidities w ere hypertension (12%), obesity (n = 14%) and diabetes mellitus (9%). An increase by a median of 2. 0 (IQR 1.4) times the daily replacement dose was reported in 42 (74%) patie nts. Two patients were administered i.m. injection of 100 mg hydrocortisone, and 11/64 were admitted to the hospital. Two patients had to be transferred to the intensive care unit, one with a fatal outcome. Four patients reported persistent SARS-CoV-2 inf ection, all others complete remission.
Conclusion: This European multicentre questionnaire is the first to collect data on the outcome of COVID-19 infection in patients with adrenal gland disorders. It suggests good clinical outcomes in case of duly dose adjustments and emphasiz es the importance of patient education on sick day rules. |
| first_indexed | 2024-04-10T03:22:32Z |
| format | Article |
| id | doaj.art-c44643f6264f41f2a57e32d1cded770a |
| institution | Directory Open Access Journal |
| issn | 2049-3614 |
| language | English |
| last_indexed | 2024-04-10T03:22:32Z |
| publishDate | 2023-03-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-c44643f6264f41f2a57e32d1cded770a2023-03-13T07:31:02ZengBioscientificaEndocrine Connections2049-36142023-03-0112419https://doi.org/10.1530/EC-22-0416Outcome of COVID-19 infections in patients with adrenal insufficiency and excessHanna F Nowotny0Jillian Bryce1Salma R Ali2Roberta Giordano3Federico Baronio4Irina Chifu5Lea Tschaidse6Martine Cools7Erica LT van den Akker8Henrik Falhammar9Natasha M Appelman-Dijkstra10Luca Persani11Guglielmo Beccuti12Ian L Ross13Simona Grozinsky-Glasberg14Alberto M Pereira15Eystein S Husebye16Stefanie Hahner17S Faisal Ahmed18Nicole Reisch19Medizinische Klinik IV, Department of Endocrinology, Klinikum der Universität München, Munich, GermanyOffice for Rare Conditions, University of Glasgow, Glasgow, UKOffice for Rare Conditions, University of Glasgow, Glasgow, UKDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy; Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy Pediatric Unit, Department Hospital of Woman and Child, Endo-ERN Centre IT11, IRCSS AOU S.Orsola-Malpighi University Hospital, Bologna, ItalyDivision of Endocrinology and Diabetology, Department of Internal Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, GermanyMedizinische Klinik IV, Department of Endocrinology, Klinikum der Universität München, Munich, GermanyDepartment of Paediatric Endocrinology, Ghent University Hospital, University of Ghent, Ghent, BelgiumDepartment of Pediatrics, Division of Pediatric Endocrinology, Erasmus MC - Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, The NetherlandsDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan Italy Department of Clinical and Biological Sciences, University of Turin, Turin, ItalyDivision of Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South AfricaNeuroendocrine Tumor Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism, Hadassah Medical Organisation and Faculty of Medicine, the Hebrew University, Jerusalem, IsraelDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Clinical Science and KG Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway; Department of Medicine, Karolinska Institutet, Stockholm, Sweden Division of Endocrinology and Diabetology, Department of Internal Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, GermanyOffice for Rare Conditions, University of Glasgow, Glasgow, UK; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Developmental Endocrinology Research Group, University of Glasgow, Glasgow, United Kingdom Medizinische Klinik IV, Department of Endocrinology, Klinikum der Universität München, Munich, GermanyBackground: Information on clinical outcomes of coronavirus disease 19 (COVID-19) infection in patients with adrenal disorders is scarce. Methods: A collaboration between the European Society of Endocrinology (ESE) Rare Disease Committee and European Reference Network on Rare Endocrine Conditions via the European Registries for Rare Endocrine Conditions allowed the collection of data on 64 cases (57 adrenal insufficiency (AI), 7 Cushing’s syndrome) th at had been reported by 12 centres in 8 European countries between January 2020 and Dec ember 2021. Results: Of all 64 patients, 23 were males and 41 females (13 of those children) with a median age of 37 and 51 years. In 45/57 (95%) AI cases, COVID -19 infection was confirmed by testing. Primary insufficiency was present in 45/57 p atients; 19 were affected by Addison’s disease, 19 by congenital adrenal hyperpla sia and 7 by primary AI (PAI) due to other causes. The most relevant comorbidities w ere hypertension (12%), obesity (n = 14%) and diabetes mellitus (9%). An increase by a median of 2. 0 (IQR 1.4) times the daily replacement dose was reported in 42 (74%) patie nts. Two patients were administered i.m. injection of 100 mg hydrocortisone, and 11/64 were admitted to the hospital. Two patients had to be transferred to the intensive care unit, one with a fatal outcome. Four patients reported persistent SARS-CoV-2 inf ection, all others complete remission. Conclusion: This European multicentre questionnaire is the first to collect data on the outcome of COVID-19 infection in patients with adrenal gland disorders. It suggests good clinical outcomes in case of duly dose adjustments and emphasiz es the importance of patient education on sick day rules.https://ec.bioscientifica.com/view/journals/ec/12/4/EC-22-0416.xmladrenal insufficiencycushing’s syndromeglucocorticoidssars-cov-2 |
| spellingShingle | Hanna F Nowotny Jillian Bryce Salma R Ali Roberta Giordano Federico Baronio Irina Chifu Lea Tschaidse Martine Cools Erica LT van den Akker Henrik Falhammar Natasha M Appelman-Dijkstra Luca Persani Guglielmo Beccuti Ian L Ross Simona Grozinsky-Glasberg Alberto M Pereira Eystein S Husebye Stefanie Hahner S Faisal Ahmed Nicole Reisch Outcome of COVID-19 infections in patients with adrenal insufficiency and excess Endocrine Connections adrenal insufficiency cushing’s syndrome glucocorticoids sars-cov-2 |
| title | Outcome of COVID-19 infections in patients with adrenal insufficiency and excess |
| title_full | Outcome of COVID-19 infections in patients with adrenal insufficiency and excess |
| title_fullStr | Outcome of COVID-19 infections in patients with adrenal insufficiency and excess |
| title_full_unstemmed | Outcome of COVID-19 infections in patients with adrenal insufficiency and excess |
| title_short | Outcome of COVID-19 infections in patients with adrenal insufficiency and excess |
| title_sort | outcome of covid 19 infections in patients with adrenal insufficiency and excess |
| topic | adrenal insufficiency cushing’s syndrome glucocorticoids sars-cov-2 |
| url | https://ec.bioscientifica.com/view/journals/ec/12/4/EC-22-0416.xml |
| work_keys_str_mv | AT hannafnowotny outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT jillianbryce outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT salmarali outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT robertagiordano outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT federicobaronio outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT irinachifu outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT leatschaidse outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT martinecools outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT ericaltvandenakker outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT henrikfalhammar outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT natashamappelmandijkstra outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT lucapersani outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT guglielmobeccuti outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT ianlross outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT simonagrozinskyglasberg outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT albertompereira outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT eysteinshusebye outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT stefaniehahner outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT sfaisalahmed outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess AT nicolereisch outcomeofcovid19infectionsinpatientswithadrenalinsufficiencyandexcess |